Silva-Fernández Lucía, Castrejón Isabel, Bombardier Claire, Carmona Loreto
Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, Joaquín Rodrigo 2, Majadahonda, Madrid, Spain.
J Rheumatol Suppl. 2011 Mar;87:38-44. doi: 10.3899/jrheum.101073.
To evaluate the diagnostic and prognostic utility of genetic testing in undifferentiated peripheral inflammatory arthritis (UPIA).
A systematic literature search was performed in Medline, Embase, the Cochrane Library, and abstracts presented at the 2007 and 2008 meetings of the American College of Rheumatology and the European League Against Rheumatism. The target studies were those evaluating diagnostic or prognostic value of genetic markers specifically in UPIA. Two reviewers independently screened titles and abstracts and reviewed included articles in detail. All data were collected using ad hoc standard forms, permitting the calculation of positive and negative likelihood ratios of each genetic marker for diagnoses of different rheumatic diseases and for the development of relevant outcomes.
Of the 3109 articles retrieved, 26 original studies fulfilled criteria of the systematic review. The most frequent diagnosis tested was rheumatoid arthritis, followed by inflammatory polyarthritis, and spondyloarthropathies. The main prognostic outcome evaluated was development of erosions, followed by median Larsen score, remission, Health Assessment Questionnaire (HAQ) score, and persistent synovitis. In total, 122 genetic markers were tested. No genetic marker had a high likelihood ratio for the diagnosis of a specific rheumatic disease. The shared epitope was associated with poor prognosis (erosions, HAQ > 1, mortality, and persistent synovitis). Other genes did not predict outcome in undifferentiated arthritis. Other outcomes for persistent disease or disability were not studied in depth.
In isolation, no studied genetic marker is very informative of a future diagnosis in patients with UPIA. The shared epitope has a slight association with poor prognosis of UPIA.
评估基因检测在未分化外周炎性关节炎(UPIA)中的诊断及预后价值。
在Medline、Embase、Cochrane图书馆以及2007年和2008年美国风湿病学会与欧洲抗风湿病联盟会议上发表的摘要中进行系统的文献检索。目标研究为那些专门评估基因标志物在UPIA中的诊断或预后价值的研究。两名评审员独立筛选标题和摘要,并详细审阅纳入的文章。所有数据均使用特设标准表格收集,从而能够计算每个基因标志物对不同风湿性疾病诊断及相关结局发生的阳性和阴性似然比。
在检索到的3109篇文章中,26项原始研究符合系统评价标准。检测频率最高的诊断是类风湿关节炎,其次是炎性多关节炎和脊柱关节炎。评估的主要预后结局是侵蚀的发生,其次是Larsen中位数评分、缓解、健康评估问卷(HAQ)评分和持续性滑膜炎。总共检测了122个基因标志物。没有基因标志物对特定风湿性疾病的诊断具有高似然比。共同表位与预后不良(侵蚀、HAQ>1、死亡率和持续性滑膜炎)相关。其他基因不能预测未分化关节炎的结局。未深入研究持续性疾病或残疾的其他结局。
单独来看,没有一个研究的基因标志物对UPIA患者的未来诊断有很大参考价值。共同表位与UPIA的不良预后有轻微关联。